Monday, November 8, 2021 – 23:26 WIB
–
VIVA – The pharmaceutical company Regeneron Pharmaceuticals, claims that the mixture drug His single-dose antibody was able to reduce the risk of exposure to COVID-19 by up to 81.6 percent over a period of 2-8 months, following the administration of the drug in a late-stage trial.
Test results show that the antibody drug, REGEN-CoV, has the potential to provide long-lasting immunity against COVID-19 infection, said Myron Cohen, Monday, November 8, 2021.
Cohen is leading the effort to develop monoclonal antibodies for the COVID-19 Prevention Network sponsored by the US National Institutes of Health.
Such immunity is especially important for immunocompromised people and people who don’t respond to vaccines, the company said.
The treatment had previously shown an 81.4 percent reduction in risk during the first month after it was administered.
During the eight-month evaluation period, there were no hospitalized COVID-19 patients in the REGEN-CoV group. However, from the placebo group there were six people who were hospitalized, Regeneron said.
US health regulators in July expanded the authorization of REGEN-CoV, which would allow it to be used as a preventative drug in people who come into contact with people infected with the virus, as well as in those at high risk of exposure in places such as nursing homes or prisons.
REGEN-COV received US regulatory clearance in November last year to treat mild to moderate COVID-19 cases. (Ant/Between)
–
